FLT3 and acute myeloid leukemia: Intriguingly, Wang Y et al. found a statistically significant worse progression-free survival (PFS) and non-OS for AML patients with NPM1 and MRG mutations, even though patients with concomitant FLT3-ITD mutations exhibited OS and PFS comparable to those with MRGs [97].